BIBLIOGRAPHY
- Anderson, Arthur and Company. Executive Summary of the PMA Cost of Regulation Study. Economic Costs of FDA Regulations: A Set of Studies of Some Economic Effects of Food and Drug Administration Regulation of Human Pharmaceuticals. Pharmaceutical Manufacturers Association, Washington, D.C. March, 1981
- Eisman M. M., Wardell W. M. Incremental Time Study: An Analysis of Time Spent in the Development and Approval of Drugs for the U.S. Market. Economic Costs of FDA Regulations: A Set of Studies of Some Economic Effects of Food and Drug Administration Regulation of Human Pharmaceuticals. Pharmaceutical Manufacturers Association, Washington, D.C. March, 1981
- Grabowski H. G. Drug Regulation and Innovation. Empirical Evidence and Policy Options. American Enterprise Institute, Washington, D.C. 1976
- Grabowski H. G. Public Policy and. Innovation: The Case of Pharmaceuticals. Technovation 1982; Vol. 1: 157–189
- Grabowski H. G., Vernon J. M., Thomas L. G. Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry. J. Law and Economics 1978; Vol. 21: 133–164
- Hansen, Ronald W. Effects of Incremental Costs on Pharmaceutical Innovation. Economic Costs of FDA Regulations: A Set of Studies of Some Economic Effects of Food and Drug Administration Regulation of Human Pharmaceuticals. Pharmaceutical Manufacturers Association, Washington, D.C. March, 1981
- Levin Arthur. Regulating health Care. Proceedings of the Academy of Political Science 1980; Vol. 33(No. 4)
- Orzel, Rita A. An Analysis of Notices of Claimed Investigational Exemption for a New Drug. University of Pittsburgh. 1972, Ph.D. Dissertation
- Pharmaceutical Manufacturers Association. PMA 1979–1980 Annual Survey Report: U.S. Pharmaceutical Industry. Pharmaceutical Manufacturers Association, Washington, D.C. 1980
- Pharmaceutical Manufacturers Association. Prescription Drug Industry: Pharmaceuticals, Medical Devices and Diagnostic Products – Fact Rook 1980. Pharmaceutical Manufacturers Association, Washington, D.C. 1980
- Poggiolini D. The Acceptance of International Clinical Data. Symposium on International Drug Registration. International Federation of Pharmaceutical Manufacturers Association, GenevaSwitzerland October 2–5, 1979
- , Public Law 87–781, Statute 780
- June 30, 1906, Public Law 384, 59th congress
- June 25, 1938, Public Law 717, 75th congress
- Schwartzman David. Innovation in the Pharmaceutical Industry. The John Hopkins University Press, Baltimore 1976
- United States General Accounting, H.R.D. 80–64. FDA Drug Approval: A L Process that Delays the Availability of Important New Drugs. United States General Accounting Office, Washington, D.C. May 28, 1980
- Wardell W. M. Introduction of New Therapeutic Drugs in the United States and Great Britain: An International Comparison. Clinical Pharmacology and Therapeutics 1973; Vol. 14: 773–790
- Wardell W. M., Hassar M., Anavekar S. N. The Rate of Development of New Drugs in the United States. Clinical Pharmacology and Therapeutics 1978; Vol. 24: 133–145
- Federal Register Feb. 22, 1985; Vol. 50: 7452–7456, #36, - Effective Date (7)
- Regulatory Affairs Management in the Pharmaceutical Industry. Draft Guidelines For the Preparation of NDA, East Brunswick, N.J. Sept. 8–10, 1986; 6, Barb Matlosz Section E
- Reg. Affairs Mgt. in the Pharm. Industry. East Brunswick, N.J. Draft Guidelines For the Preparation of NDA, Barb Matlosz - Section E. Sept 8–10, 1986; 5
- Ibid. 44
- Ibid. 18
- Federal Register Feb. 22, 1985; Vol. 50: 7457, #36
- Drug Development and Industrial Pharmacy 1985; 11(5)1001–1018, “Aspects of Regulatory Requirements in Industrialized Countries”, Anthony S. Anginoli, Schering-Plough Corporation, Kenilsworth, N. J., p. 1003, 1007
- Federal Register Feb. 22, 1985; Vol. 50: 7459–60, #36
- Federal Register Feb. 22, 1985; Vol 50: 7460, #36, (29), (314.50(d)) (2)
- Federal Register Feb. 22, 1985; Vol. 50(No. 36)7460–1, (Section 314.50 (d) (3)) Human Pharmacokinetics and Bioavailability
- Federal Register Feb. 22, 1985; Vol. 50: 7462, #36, Clinical Data Section – General (324.50 (d) (5)
- Federal Register Feb. 22, 1985; Vol. 50: 7468, #36, Adequate and Well-Controlled Studies (314.126)
- Federal Register Feb. 22, 1985; Vol. 50: 7462, #36, Clinical Data Section - General (314.50 (d) (5)) #38
- Federal Register Feb. 22, 1985; Vol. 50: 7453, #36, Foreign Data Section – Highlights of the Final Rule (d5)
- Wall Street Journal
- Federal Register Feb. 22, 1985; Vol. 50: 7462, #36, Safety Update Reports (314.50 (d) (5) (vi) (b))
- Regulatory Affairs Management in the Pharamaceutical Industry. Sept. 8–10, 1986; 5, East Brunswick, NJ, Section K - Barbara Kostiuk
- Ibid. 6, Section K - Barbara Kostiuk
- Ibid.
- Ibid. 8
- Regulatory Affairs Management in the Pharmaceutical Industry. Sept. 8–10, 1986; 31–43, East Brunswick, NJ, Section K - Barbara Kostius
- Regulatory Affairs Management in the Pharmaceutical Industry. Op. cit. Feb. 22, 1985; Vol. 50: 7471, #36, Section K - Barbara Kostiuk, p. 45, pp, 7, 9, 11, 13. Federal Register, (D23), Requirements for 15-day alert
- Ibid.
- Ibid.
- Federal Register Feb. 22, 1985; Vol. 50: 7485, (D37). #36, Approvable and Not Approvable Letters (314.50/324.120)
- Ibid.
- Ibid.
- Federal Register Feb. 22, 1985; Vol. 50: 7460, #36, Human Pharmacokinetics and Bioavailability Section - (314.50 (d) (3)). Part 320 - NDA rewrite (D68)
- Federal Register Feb. 22, 1985; Vol. 50: 7478–9, #36, Time Framer for Reviewing Applications (314.100), #97, 98
- Federal Register Feb. 22, 1985; Vol. 50: 7480–1, #36, Dispute Resolutions (Section 314.103)
- Ibid. 7478–9
- Regulatory Affairs Management in the Pharmaceutical Industry. Sept. 8–10, 1986; 1–2, East Brunsvick, NJ. Follow Up Submissions - Barbara Matlosz (Section H)
- Ibid. 2–3
- Ibid.
- Reich, Jack W., Daniel Hilleman E. A Geocentric Approach to Pharmacetuical Research and Development and Drug Regulatory Affairs. Clinical Research Practices & Drug Regulatory Affairs 1985; Vol. 3(1)1–22